Oncodesign SA
20 rue Jean Mazen
B.P. 27627
Dijon
Cedex
21076
France
Tel: 33-3-80-78-82-60
Fax: 33-3-80-78-82-61
Website: http://www.oncodesign.com/
Email: contact@oncodesign.fr
37 articles about Oncodesign SA
-
SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
2/8/2022
SEngine Precision Medicine Inc. and Oncodesign have announced the signature of a research collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
-
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
10/21/2021
Oncodesign, a French biopharmaceutical company specialized in kinase inhibitor research and precision medicine, and TiumBio, a company specializing in R&D for rare diseases, have announced the signature of a research collaboration agreement on R&D of potential drug candidates for fibrosis.
-
BioSpace Global Roundup, June 4
6/4/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Parkinson's disease: Servier and Oncodesign join forces to investigate new line of research
3/11/2019
Servier to be granted option to exclusively license one or several drug candidates as soon as they are approved to enter phase 1
-
Service Partnership Agreement between Oncodesign and Galderma
11/7/2018
Oncodesign (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, is announcing a service partnership with Galderma, a dermatological unit belonging to Nestlé Skin Health.
-
Oncodesign: Promising Clinical Results for Innovative Mutated anti-EGFR Radiotracer in Patients With Non-Small Cell Lung Cancer
12/18/2017
The first stage of the clinical trial, in 8 patients with EGFR mutations, has produced very encouraging results in terms of product safety, dosage and fixing on pulmonary tumors expressing mutated EGFR.
-
Oncodesign Announces Positive Results Opening the Way for The ALK1 Program to Advance to the Lead Optimization Phase
11/15/2017
The company has obtained positive results opening the way for the ALK1 kinase inhibitor discovery program to move on to the lead optimization phase.
-
OncoSNIPE Artificial Intelligence Project Officially Launched
10/19/2017
Oncodesign, a biopharmaceutical group specialized in precision medicine, and UNICANCER present the details of the OncoSNIPE project, which aims to develop and apply artificial intelligence techniques to cancer research.
-
Oncodesign SA Presents Its Latest Scientific Developments At The AACR Annual Global Meeting On Oncology
4/3/2017
-
Oncodesign SA Completes The Acquisition Of François Hyafil Research Centre And Appoints Two New Strategic Activity Directors
12/1/2016
-
GlaxoSmithKline And Oncodesign SA Announce Agreement For Oncodesign’s Acquisition Of GSK’s Research Centre In France
9/28/2016
-
Oncodesign SA Announces The Launch Of Its First Clinical Study On A Radiotracer In Patients With Non-Small Cell Lung Cancer
7/13/2016
-
Oncodesign SA And Ipsen Enter Into A Strategic Partnership In Oncology And Oncodesign Joins Ipsen’s Paris-Saclay Campus
5/3/2016
-
Bristol-Myers Squibb, Oncodesign SA Knock Out a $83 Million+ Drug Discovery Pact
1/5/2016
-
Preclinical Validation Of Oncodesign SA’s First Radiotracer Prior To Human Application
12/17/2015
-
Oncodesign SA Presents Novel LRRK2 Inhibitor Jointly Discovered With Ipsen At The 2015 Neurosciences Meeting In Chicago
10/22/2015
-
UCB Exercises Its Option To License A Program From Oncodesign SA Targeting Neurological Diseases
6/5/2015
-
Oncodesign SA Has Entered Into A Services Agreement With Eisai Inc. To Develop A New Personalized Medicine Program In Earlier Line Metastatic Breast Cancer Treatment
12/17/2014
-
Oncodesign SA: 1st Half Of 2014
7/23/2014
-
Oncodesign SA And UCB, Inc. Enter Into A Research Collaboration For The Early Development Of New Therapeutic Agents In Neurodegenerative Diseases
11/13/2013